BRPI0819191A2 - uso de oligonucleotídeos com bases modificadas como agentes antivirais. - Google Patents

uso de oligonucleotídeos com bases modificadas como agentes antivirais.

Info

Publication number
BRPI0819191A2
BRPI0819191A2 BRPI0819191A BRPI0819191A BRPI0819191A2 BR PI0819191 A2 BRPI0819191 A2 BR PI0819191A2 BR PI0819191 A BRPI0819191 A BR PI0819191A BR PI0819191 A BRPI0819191 A BR PI0819191A BR PI0819191 A2 BRPI0819191 A2 BR PI0819191A2
Authority
BR
Brazil
Prior art keywords
base
antiviral agents
modified oligonucleotides
oligonucleotides
modified
Prior art date
Application number
BRPI0819191A
Other languages
English (en)
Portuguese (pt)
Inventor
Merits Andres
Saarma Mart
Karelson Mati
Original Assignee
Baltic Tech Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baltic Tech Dev Ltd filed Critical Baltic Tech Dev Ltd
Publication of BRPI0819191A2 publication Critical patent/BRPI0819191A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0819191A 2007-11-05 2008-11-05 uso de oligonucleotídeos com bases modificadas como agentes antivirais. BRPI0819191A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98554807P 2007-11-05 2007-11-05
US5768508P 2008-05-30 2008-05-30
PCT/FI2008/050633 WO2009060122A2 (en) 2007-11-05 2008-11-05 Use of oligonucleotides with modified bases as antiviral agents

Publications (1)

Publication Number Publication Date
BRPI0819191A2 true BRPI0819191A2 (pt) 2017-03-21

Family

ID=40551515

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819191A BRPI0819191A2 (pt) 2007-11-05 2008-11-05 uso de oligonucleotídeos com bases modificadas como agentes antivirais.

Country Status (10)

Country Link
US (1) US20110171287A1 (cg-RX-API-DMAC7.html)
EP (1) EP2212420A2 (cg-RX-API-DMAC7.html)
JP (1) JP5710977B2 (cg-RX-API-DMAC7.html)
CN (1) CN101970662A (cg-RX-API-DMAC7.html)
AU (1) AU2008324066A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0819191A2 (cg-RX-API-DMAC7.html)
CA (1) CA2704549A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010004983A (cg-RX-API-DMAC7.html)
WO (1) WO2009060122A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201003234B (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2704560A1 (en) * 2007-11-05 2009-05-14 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases in hybridization of nucleic acids
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2009144365A1 (en) * 2008-05-30 2009-12-03 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases as antiviral agents
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
NZ601784A (en) 2010-03-08 2014-08-29 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
BR112014005951A2 (pt) 2011-09-13 2017-04-04 Monsanto Technology Llc métodos e composições para controle de erva daninha
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
AU2012308686B2 (en) 2011-09-13 2018-05-10 Monsanto Technology Llc Methods and compositions for weed control
US9416363B2 (en) 2011-09-13 2016-08-16 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
EP2756086B1 (en) 2011-09-13 2018-02-21 Monsanto Technology LLC Methods and compositions for weed control
BR112014005963A2 (pt) 2011-09-13 2020-12-08 Monsanto Technology Llc métodos de controle de planta, de redução de expressão de um gene als em uma planta, de identificação de polinucleotídeos úteis na modulação de expressão do gene als, de fazer um polinucleotídeo, composições compreendendo um polinucleotídeo e um agente de transferência ou um herbicida, cassete de expressão microbiana, bem como molécula de polinucleotídeo
WO2013040117A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
AU2012308753B2 (en) 2011-09-13 2018-05-17 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
WO2013040057A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
EP2855680B8 (en) 2012-05-24 2020-04-15 Monsanto Technology LLC Compositions and methods for silencing gene expression
WO2013185067A1 (en) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014047653A2 (en) 2012-09-24 2014-03-27 Seminis Vegetable Seeds, Inc. Methods and compositions for extending shelf life of plant products
US10077451B2 (en) 2012-10-18 2018-09-18 Monsanto Technology Llc Methods and compositions for plant pest control
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
FR2997705B1 (fr) * 2012-11-08 2015-10-16 Nicolas Ugolin Nucleotide 3' bloquant la traduction des proteines (sasb)
AU2013371825B2 (en) 2013-01-01 2019-10-24 A.B. Seeds Ltd. Methods of introducing dsRNA to plant seeds for modulating gene expression
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
CA2897458A1 (en) 2013-01-15 2014-07-24 Monsanto Technology Llc Methods and compositions for plant pest control
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
BR112015022797A2 (pt) 2013-03-13 2017-11-07 Monsanto Technology Llc método para controle de ervas daninhas, composição herbicida, cassete de expressão microbiano e método de produção de polinucleotídeo
EP2971185A4 (en) 2013-03-13 2017-03-08 Monsanto Technology LLC Methods and compositions for weed control
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
MX359191B (es) 2013-07-19 2018-09-18 Monsanto Technology Llc Composiciones y métodos para controlar leptinotarsa.
UA120426C2 (uk) 2013-11-04 2019-12-10 Монсанто Текнолоджі Елелсі Композиція та спосіб для боротьби з членистоногими паразитами та зараженням шкідниками
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
BR112016016337A2 (pt) 2014-01-15 2017-10-03 Monsanto Technology Llc Composição e métodos para controlar crescimento, desenvolvimento ou a capacidade de reprodução de uma planta, e para sensibilizar uma planta para um herbicida inibidor de epsps
CN110506752B (zh) 2014-04-01 2022-02-18 孟山都技术公司 用于控制虫害的组合物和方法
EP3158067B1 (en) 2014-06-23 2020-08-12 Monsanto Technology LLC Compositions and methods for regulating gene expression via rna interference
WO2015200539A1 (en) 2014-06-25 2015-12-30 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US10378012B2 (en) 2014-07-29 2019-08-13 Monsanto Technology Llc Compositions and methods for controlling insect pests
EP3183007B1 (en) * 2014-08-19 2020-06-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
UA124255C2 (uk) 2015-01-22 2021-08-18 Монсанто Текнолоджі Елелсі Інсектицидна композиція та спосіб боротьби з leptinotarsa
UY36703A (es) 2015-06-02 2016-12-30 Monsanto Technology Llc Composiciones y métodos para la administración de un polinucleótido en una planta
AU2016270913A1 (en) 2015-06-03 2018-01-04 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
EP3408390A4 (en) 2016-01-26 2019-10-09 Monsanto Technology LLC COMPOSITIONS AND METHODS FOR COMBATING INSECTS
CN117677586A (zh) * 2022-06-13 2024-03-08 菲克雷丁·萨欣 镥盐化合物用于抗病毒作用的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501058A (ja) * 1989-12-04 1993-03-04 アイシス・ファーマシューティカルス・インコーポレーテッド 乳頭腫ウイルス属のアンチセンスオリゴヌクレオチド阻害
JP2823959B2 (ja) * 1991-10-24 1998-11-11 アイシス・ファーマシューティカルス・インコーポレーテッド 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド
US5684149A (en) * 1993-01-22 1997-11-04 Research Foundation Of State University Of New York Metal complexes for promoting catalytic cleavage of RNA by transesterification
DE4415370A1 (de) * 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US20040171030A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
US20030064944A1 (en) * 2001-06-21 2003-04-03 Isis Pharmaceuticals Inc. Antisense modulation of transforming growth factor beta receptor II expression
AU2003241621A1 (en) * 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
WO2003106477A1 (en) * 2002-06-01 2003-12-24 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
US20080009455A9 (en) * 2005-02-24 2008-01-10 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
JP2009535383A (ja) * 2006-05-03 2009-10-01 バルティック テクロノジー デヴェロプメント，リミテッド 強く結合した塩基で修飾されたオリゴヌクレオチドと人工ヌクレアーゼを組み合わせたアンチセンス作用物質

Also Published As

Publication number Publication date
CN101970662A (zh) 2011-02-09
WO2009060122A3 (en) 2009-06-25
CA2704549A1 (en) 2009-05-14
JP5710977B2 (ja) 2015-04-30
US20110171287A1 (en) 2011-07-14
EP2212420A2 (en) 2010-08-04
WO2009060122A2 (en) 2009-05-14
ZA201003234B (en) 2011-06-29
MX2010004983A (es) 2010-07-29
AU2008324066A1 (en) 2009-05-14
JP2011502501A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
BRPI0819191A2 (pt) uso de oligonucleotídeos com bases modificadas como agentes antivirais.
BRPI0719210A2 (pt) Uso de compostos espiro-oxindol como agentes terapêuticos
BRPI0819193A2 (pt) uso de oligonucleotídeos com bases modificadas na hibridização de ácidos nucleicos.
BRPI0819797A2 (pt) compostos de nucleosídeos antivirais
BRPI0919295A2 (pt) 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
BRPI0821668A2 (pt) Uso
BRPI0916930A2 (pt) Uso de 5-fluorocitosina como um fungicida.
BRPI0815979A2 (pt) compostos e composições com inibidores de quinase, bem como uso dos mesmos
BRPI0913835A2 (pt) uso de tensoativos catiônicos como agentes esporicidas
BRPI0922508A2 (pt) Análogos de nucleosídeo
BRPI0809974A2 (pt) Compostos de pirimidina hidrazida como inibidores de pgds
BRPI0718266A2 (pt) Compostos heterocíclicos como agentes anti-inflamatórios.
BRPI0823082A2 (pt) Uso derivados de sesquiterpeno
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI0821766A2 (pt) Catalisador de ativação rápida
BRPI0913833A2 (pt) uso de corantes ácidos
ES2465673T9 (es) Derivados de pirimidina
BRPI0815246A2 (pt) Composição de catalisador
BRPI0922681A2 (pt) nucleiotídeos de uracil ciclopropila
BRPI0910534A2 (pt) terapia antiviral
BRPI0811115A2 (pt) Compostos de heteroarilamida pirimidona
BRPI0815596A2 (pt) Uso de compostos de sulfonanilida como herbicida
BRPI0913267A2 (pt) uso do ácido succínico
BRPI0811132A2 (pt) Preparação de catalisadores de paládio-ouro

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]